157 related articles for article (PubMed ID: 28667595)
1. Optimizing bevacizumab dosing in glioblastoma: less is more.
Ajlan A; Thomas P; Albakr A; Nagpal S; Recht L
J Neurooncol; 2017 Oct; 135(1):99-105. PubMed ID: 28667595
[TBL] [Abstract][Full Text] [Related]
2. Toxicity and efficacy of lomustine and bevacizumab in recurrent glioblastoma patients.
Jakobsen JN; Urup T; Grunnet K; Toft A; Johansen MD; Poulsen SH; Christensen IJ; Muhic A; Poulsen HS
J Neurooncol; 2018 Apr; 137(2):439-446. PubMed ID: 29330749
[TBL] [Abstract][Full Text] [Related]
3. Effect of angiotensin system inhibitors on survival in newly diagnosed glioma patients and recurrent glioblastoma patients receiving chemotherapy and/or bevacizumab.
Levin VA; Chan J; Datta M; Yee JL; Jain RK
J Neurooncol; 2017 Sep; 134(2):325-330. PubMed ID: 28631191
[TBL] [Abstract][Full Text] [Related]
4. Hypofractionated re-irradiation with bevacizumab for relapsed chemorefractory glioblastoma after prior high dose radiotherapy: a feasible option for patients with large-volume relapse.
Tong E; Horsley P; Wheeler H; Wong M; Venkatesha V; Chan J; Kastelan M; Back M
J Neurooncol; 2024 May; 168(1):69-76. PubMed ID: 38551747
[TBL] [Abstract][Full Text] [Related]
5. Impact of bevacizumab administered dose on overall survival of patients with progressive glioblastoma.
Levin VA; Mendelssohn ND; Chan J; Stovall MC; Peak SJ; Yee JL; Hui RL; Chen DM
J Neurooncol; 2015 Mar; 122(1):145-50. PubMed ID: 25575937
[TBL] [Abstract][Full Text] [Related]
6. Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O
Cloughesy T; Finocchiaro G; Belda-Iniesta C; Recht L; Brandes AA; Pineda E; Mikkelsen T; Chinot OL; Balana C; Macdonald DR; Westphal M; Hopkins K; Weller M; Bais C; Sandmann T; Bruey JM; Koeppen H; Liu B; Verret W; Phan SC; Shames DS
J Clin Oncol; 2017 Jan; 35(3):343-351. PubMed ID: 27918718
[TBL] [Abstract][Full Text] [Related]
7. Clinical outcomes in recurrent glioblastoma with bevacizumab therapy: An analysis of the literature.
Tipping M; Eickhoff J; Ian Robins H
J Clin Neurosci; 2017 Oct; 44():101-106. PubMed ID: 28711289
[TBL] [Abstract][Full Text] [Related]
8. Progression-free and overall survival in patients with recurrent Glioblastoma multiforme treated with last-line bevacizumab versus bevacizumab/lomustine.
Heiland DH; Masalha W; Franco P; Machein MR; Weyerbrock A
J Neurooncol; 2016 Feb; 126(3):567-75. PubMed ID: 26614518
[TBL] [Abstract][Full Text] [Related]
9. Dexamethasone administration during definitive radiation and temozolomide renders a poor prognosis in a retrospective analysis of newly diagnosed glioblastoma patients.
Shields LB; Shelton BJ; Shearer AJ; Chen L; Sun DA; Parsons S; Bourne TD; LaRocca R; Spalding AC
Radiat Oncol; 2015 Oct; 10():222. PubMed ID: 26520780
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant bevacizumab and irinotecan versus bevacizumab and temozolomide followed by concomitant chemoradiotherapy in newly diagnosed glioblastoma multiforme: A randomized phase II study.
Hofland KF; Hansen S; Sorensen M; Engelholm S; Schultz HP; Muhic A; Grunnet K; Ask A; Costa JC; Kristiansen C; Thomsen C; Poulsen HS; Lassen U
Acta Oncol; 2014 Jul; 53(7):939-44. PubMed ID: 24456504
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors in recurrent glioblastoma patients treated with bevacizumab.
Schaub C; Tichy J; Schäfer N; Franz K; Mack F; Mittelbronn M; Kebir S; Thiepold AL; Waha A; Filmann N; Banat M; Fimmers R; Steinbach JP; Herrlinger U; Rieger J; Glas M; Bähr O
J Neurooncol; 2016 Aug; 129(1):93-100. PubMed ID: 27193554
[TBL] [Abstract][Full Text] [Related]
12. Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial.
Balana C; De Las Penas R; Sepúlveda JM; Gil-Gil MJ; Luque R; Gallego O; Carrato C; Sanz C; Reynes G; Herrero A; Ramirez JL; Pérez-Segura P; Berrocal A; Vieitez JM; Garcia A; Vazquez-Estevez S; Peralta S; Fernandez I; Henriquez I; Martinez-Garcia M; De la Cruz JJ; Capellades J; Giner P; Villà S
J Neurooncol; 2016 May; 127(3):569-79. PubMed ID: 26847813
[TBL] [Abstract][Full Text] [Related]
13. The added value of bevacizumab concomitantly administered with carboplatin versus carboplatin alone in patients with recurrent glioblastomas.
Kaloshi G; Diamandi P; Cakani B; Brace G; Rroji A; Petrela M
Tumori; 2015; 101(1):41-5. PubMed ID: 25702676
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab reduces toxicity of reirradiation in recurrent high-grade glioma.
Fleischmann DF; Jenn J; Corradini S; Ruf V; Herms J; Forbrig R; Unterrainer M; Thon N; Kreth FW; Belka C; Niyazi M
Radiother Oncol; 2019 Sep; 138():99-105. PubMed ID: 31252301
[TBL] [Abstract][Full Text] [Related]
15. Reduced-dose bevacizumab vs. standard-dose bevacizumab in recurrent high-grade glioma: Which one is better? A meta-analysis.
Chen Y; Guo L; Li X; Liu R; Ren C; Du S
Clin Neurol Neurosurg; 2020 Nov; 198():106239. PubMed ID: 33007724
[TBL] [Abstract][Full Text] [Related]
16. Role of delayed salvage bevacizumab at symptomatic progression of chemorefractory glioblastoma.
Cuncannon M; Wong M; Jayamanne D; Guo L; Cove N; Wheeler H; Back M
BMC Cancer; 2019 May; 19(1):445. PubMed ID: 31088401
[TBL] [Abstract][Full Text] [Related]
17. Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study.
Vredenburgh JJ; Cloughesy T; Samant M; Prados M; Wen PY; Mikkelsen T; Schiff D; Abrey LE; Yung WK; Paleologos N; Nicholas MK; Jensen R; Das A; Friedman HS
Oncologist; 2010; 15(12):1329-34. PubMed ID: 21147867
[TBL] [Abstract][Full Text] [Related]
18. Bevacizumab: Is the lower the better for glioblastoma patients in progression?
Sirven-Villaros L; Bourg V; Suissa L; Mondot L; Almairac F; Fontaine D; Paquis P; Burel-VandenBos F; Frenay M; Thomas P; Lebrun-Frenay C
Bull Cancer; 2018 Dec; 105(12):1135-1146. PubMed ID: 30301554
[TBL] [Abstract][Full Text] [Related]
19. Pulsed Reduced Dose Rate Radiotherapy in Conjunction With Bevacizumab or Bevacizumab Alone in Recurrent High-grade Glioma: Survival Outcomes.
Bovi JA; Prah MA; Retzlaff AA; Schmainda KM; Connelly JM; Rand SD; Marszalkowski CS; Mueller WM; Siker ML; Schultz CJ
Int J Radiat Oncol Biol Phys; 2020 Nov; 108(4):979-986. PubMed ID: 32599030
[TBL] [Abstract][Full Text] [Related]
20. Optimizing intrapleural bevacizumab dosing in non-small-cell lung cancer-mediated malignant pleural effusion: less is more.
Chen D; Song X; Zhang Y; Kong L; Wang H; Yu J
Future Oncol; 2018 Sep; 14(21):2131-2138. PubMed ID: 29546764
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]